|
June 10, 2022
|
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
|
|
|
June 1, 2022
|
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
|
|
|
May 16, 2022
|
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
|
|
|
May 12, 2022
|
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
|
|
|
May 11, 2022
|
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
|
|
|
May 9, 2022
|
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
|
|
|
May 3, 2022
|
Caribou Biosciences to Present at Upcoming Investor Conference
|
|
|
May 2, 2022
|
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
|
|
|
April 25, 2022
|
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
|
|
|
April 8, 2022
|
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
|
|
